- Home
- PRZO vs PMN Comparison
PRZO vs PMN Comparison
Compare PRZO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- PMN
- Stock Information
- Founded
- PRZO 2014
- PMN 2004
- Country
- PRZO Israel
- PMN Canada
- Employees
- PRZO N/A
- PMN N/A
- Industry
- PRZO
- PMN Pharmaceuticals and Biotechnology
- Sector
- PRZO
- PMN Health Care
- Exchange
- PRZO Nasdaq
- PMN Nasdaq
- Market Cap
- PRZO 14.8M
- PMN 17.0M
- IPO Year
- PRZO 2023
- PMN N/A
- Fundamental
- Price
- PRZO $1.29
- PMN $0.50
- Analyst Decision
- PRZO
- PMN Strong Buy
- Analyst Count
- PRZO 0
- PMN 2
- Target Price
- PRZO N/A
- PMN $4.50
- AVG Volume (30 Days)
- PRZO 1.5M
- PMN 48.8K
- Earning Date
- PRZO 03-21-2025
- PMN 08-07-2025
- Dividend Yield
- PRZO N/A
- PMN N/A
- EPS Growth
- PRZO N/A
- PMN N/A
- EPS
- PRZO N/A
- PMN N/A
- Revenue
- PRZO $932,154.00
- PMN N/A
- Revenue This Year
- PRZO N/A
- PMN N/A
- Revenue Next Year
- PRZO N/A
- PMN N/A
- P/E Ratio
- PRZO N/A
- PMN N/A
- Revenue Growth
- PRZO 50.22
- PMN N/A
- 52 Week Low
- PRZO $0.49
- PMN $0.47
- 52 Week High
- PRZO $3.16
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- PRZO 63.22
- PMN 45.69
- Support Level
- PRZO $1.10
- PMN $0.48
- Resistance Level
- PRZO $1.40
- PMN $0.53
- Average True Range (ATR)
- PRZO 0.10
- PMN 0.04
- MACD
- PRZO 0.01
- PMN 0.00
- Stochastic Oscillator
- PRZO 79.40
- PMN 25.00
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.